| Bioactivity | Rivipansel (GMI-1070) is a potent E-selectin antagonist. Rivipansel prevents interaction between leukocytes and vascular endothelium. Rivipansel has the potential for the research of sickle cell vaso-occlusive crisis[1][2]. |
| Name | Rivipansel |
| CAS | 927881-99-0 |
| Formula | C58H74N6O31S3 |
| Molar Mass | 1447.42 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Dampier CD, et al. A Randomized Clinical Trial of the Efficacy and Safety of Rivipansel for Sickle Cell Vaso-occlusive Crisis (VOC). Blood. 2022 Aug 18:blood.2022015797. [2]. Carlton D.DampierMD, et al. Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136 (1):18-19. |
Rivipansel
CAS: 927881-99-0 F: C58H74N6O31S3 W: 1447.42
Rivipansel (GMI-1070) is a potent E-selectin antagonist. Rivipansel prevents interaction between leukocytes and vascular
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.